Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-01-24
1998-03-03
Grumbling, Matthew V.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514261, 514357, 514538, 514541, 560 41, 544162, 544277, 546335, A61K 3154, A61K 31535, C07D40102, C07D40302
Patent
active
057234590
ABSTRACT:
The present invention relates to novel compounds which possess a broad range of useful biological activities. These compounds can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. They can also suppress, modify, or significantly reduce an immune response, including an autoimmune response in a mammal. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, for use in multi-drug resistant cancer therapy, and for prevention or treatment of graft rejection and various autoimmune diseases.
REFERENCES:
patent: 4296113 (1981-10-01), Omdetti
patent: 4376124 (1983-03-01), Carlson
patent: 4579840 (1986-04-01), Hahn
patent: 4920218 (1990-04-01), Askin
patent: 5135915 (1992-08-01), Czarniecki
patent: 5192773 (1993-03-01), Armistead
patent: 5274167 (1993-12-01), Lange et al.
patent: 5330993 (1994-07-01), Armistead
D. R. Bender et al., "Periodate Oxidation of .alpha.-Ketoy-Lactams. Enol Oxidation and .beta.-Lactam Formation. Mechanism of Periodate Hydroxylation Reactions", J. Org. Chem., 43(17), pp. 3354-3361 (1978).
D. Boesch et al., "In Vivo Circumvention of P-Glycoprotein-Mediated Multidrug Resistance of Tumor Cells with SDZ PSC 833", Cancer Res., 51, pp. 4226-4233 (1991).
S.P.C. Cole et al., "Overexpression of a Transporter Gene in a Multidrug Resistant Human Lung Cancer Cell Line", Science, 258, pp. 1650-1654 (1992).
R.F. Epand and R.M. Epand, "The New Potent Immunosuppressant FK-506 Reverses Multidrug Resistance in Chinese Hamster Ovary Cells", Anti-Cancer Drug Design 6, pp. 189-193 (1991).
W.N. Hait and D. T. Aftab, "Rational Design and Pre-Clinical Pharmacology of Drugs for Reversing Multidrug Resistance", Biochem. Pharmacol., 43, pp. 103-107 (1992).
W. N. Hait et al., "Activity of Cyclosporin A and a Non-Immunosuppressive Cyclosporin Against Multidrug Resistant Leukemic Cell Lines", Cancer Commun., 1(1), pp. 35-43 (1989).
X.F. Hu et al., "Combined Use of Cyclosporin A and Verapamil in Modulating Multidrug Resistance in Human Leukemia Cell Lines", Cancer Res., 50, pp. 2953-2957 (1990).
G. Jedlitschky et al., "ATP-Dependent Transport of Glutathione S-conjugates by the Multidrug Resistance-Associated Protein", Cancer Res., 54, 4833-4836 (1994).
N. Krishnamachary et al., "The MRP Gene Associated with a Non-P-Glycoprotein Multidrug Resistance Encodes a 190-kDa Membrane Bound Glycoprotein", Cancer Res., 53, 3658-3661 (1993).
I. Leier et al., "The MRP Gene Encodes an ATP-Dependent Export Pump for Leukotriene C.sub.4 and Structurally Related Conjugates", J.Biol.Chem., 269, pp. 27807-27810 (1994).
M. Muller et al., "Overexpression of the Gene Encoding the Multi-Drug Resistance-Associated Protein Results in Increased APT-Dependent Glutathione S-Conjugate Transport," Proc. Natl. Acad. Sci. USA, 91, pp. 13033-13037 (1994).
E. Schneider et al., "Multidrug Resistance-Associated Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a Human Breast Carcinoma MCF7 Cell Line Selected for Etopside Resistance", Cancer Res., 54, pp. 152-158 (1994).
L. M. Slater et al., "Cyclosporin A Corrects Daunorubicin Resistance in Ehrlich Ascites Carcinoma", Br. J. Cancer, 54, pp. 235-238 (1986).
K. Soai et al., "Asymmetric Allylation of .alpha.-Keto Amides Derived from (S)-Proline Esters", Peptide Chemistry 1986, Proceedings of the 24th Symposium on Peptide Chemistry, (T. Miyazawa, Ed., Protein Research Foundation) pp. 327-330 (1987).
P.R. Twentyman, "Cyclosporins as Drug Resistance Modifiers", Biochem. Pharmacol., 43, pp. 109-117 (1992).
P.R. Twentyman et al., "Cyclosporin A and Its Analogues as Modifiers of Adriamycin and Vincristine Resistance in a Multi-drug Resistant Human Lung Cancer Cell Line", Br.J.Cancer, 56, pp. 55-57 (1987).
I.C. West, "What Determines the Substrate Specificity of the Multi-Drug-Resistance Pump?", TIBS, 15, pp. 42-46 (1990).
Armistead David M.
Boger Joshua S.
Harding Matthew W.
Saunders Jeffrey O.
Grumbling Matthew V.
Haley, Jr. James F.
Marks Andrew S.
Vertex Pharmaceuticals Incorporated
LandOfFree
Biologically active acylated amino acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biologically active acylated amino acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active acylated amino acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2247806